English-language podcasts

BioCentury This Week

Ep. 396 - China’s first-order innovation

30 min

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

Rising first-in-class innovation, faster IND reviews and deep patient pools are drawing global biotechs to China, even as U.S. outbound investment restrictions loom. In a special edition of the BioCentury This Week podcast recorded live at the 13th BioCentury-BayHelix China Healthcare Summit in Shanghai, BioCentury’s Jeff Cranmer, Simone Fishburn and Josh Berlin are joined by Kali Therapeutics CEO Weihao Xu, Charles River’s Matthew Hewitt and Aerska CEO Jack O’Meara to discuss key themes from the event. The panel assesses what the COINS Act could mean for U.S. investment in China biotech and how investors may adapt, how China’s 30-day IND review and new investigator-initiated trial rules are reshaping clinical strategy, and what dealmaking reveals about the country’s growing first-in-class pipeline. They also preview BioCentury’s East-West Summit in Seoul (https://conferences.biocentury.com/east-west-summit), March 15-17. View full story: https://www.biocentury.com/article/661483 #ChinaBiotech #COINSAct #ClinicalTrials #FirstInClass #BiotechPartnering 0:00 Live from China Healthcare Summit 5:20 China's Role in Biotech R&D 9:06 What COINS Could Mean for U.S. Investors 11:37 Faster IND Reviews and New IIT Rules 17:27 First-Order Innovation in China

Episode information is provided by the publisher. Listening takes place on the publisher’s service.

Listen at the source ↗

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

More from BioCentury This Week

BioCentury This Week

Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds

29 min

J&J will pay $2.2 billion upfront to acquire Ollin (https://www.biocentury.com/article/661621), a Texas-based NewCo with China-sourced assets, gaining a late-stage VEGF x Ang2 bispecific for wet AMD and diabetic macular edema. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the terms of the deal, what it says about NewCos as an exit path and Blackstone Life Sciences’ role in funding Phase III. The analysts also assess how a growing neoantigen vaccine pipeline (https://www.biocentury.com/article/661439) is testing the modality’s reach after Merck and Moderna’s Phase III win in melanoma, and the White House push (https://www.biocentury.com/article/661564) that has put Heidi Overton back in play ahead of the Nov. 18 Senate HELP Committee vote on her nomination as FDA commissioner. This episode of the BioCentury This Week podcast has been brought to you by Tigermed (https://www.tigermedgrp.com/). View full story: https://www.biocentury.com/article/661638 #NewCos #

Discuss this episode

BioCentury This Week

Ep. 397 - What the U.S. midterms mean for biopharma

29 min

Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner (https://www.biocentury.com/article/661541) and could open a narrow path to bipartisan drug pricing legislation (https://www.biocentury.com/article/661503). On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the results mean for FDA and HHS leadership, user fee negotiations, vaccine regulation, and the prospect of applying most-favored nation pricing to Medicare drug price negotiation. The analysts also unpack full Phase III data (https://www.biocentury.com/article/661524) showing pelacarsen failed across all subgroups and what it means for Lp(a) as a cardio target, highlight SITC abstracts (https://www.biocentury.com/article/661478) on localizing immunotherapy within solid tumors, and discuss argenx’s $550 million upfront buyout (https://www.biocentury.com/article/661512) of Unnatural Products. This episode of the BioCentury This Week podcast has be

Discuss this episode

Community Poll

Emergency powers should expire automatically unless publicly renewed.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

One slice of pizza remains and everyone is pretending not to want it. Can you take it?

Six friends have been circling the last slice of pizza for twenty minutes. Nobody claims it when you ask, yet two people keep glancing at the box. You are still hungry and paid the same share as everyone else.

Does politeness require leaving something that nobody will openly claim?

Explore this quandary